{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T16:42:36Z","timestamp":1791650556117,"version":"4.3.4"},"reference-count":50,"publisher":"BMJ","issue":"10","funder":[{"name":"HKU Start-up Fund","award":["XJZ"],"award-info":[{"award-number":["XJZ"]}]},{"name":"Health and Medical Research Fund","award":["11220196 [XJZ]"],"award-info":[{"award-number":["11220196 [XJZ]"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2026,3,11]]},"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:sec>\n                    <jats:title>Background\/aims<\/jats:title>\n                    <jats:p>Although 0.01% atropine is widely used for myopia control, its efficacy is debated and its effectiveness across different ethnicities is unknown. We aim to evaluate its efficacy in different ethnic backgrounds.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The randomised clinical trials (RCTs) that compared 0.01% atropine against a placebo in myopic children from five databases through August 2025 were included. The primary outcomes included (1) the ratio of the means (RoM), defined as the RoM of annual changes in spherical equivalent refraction (SER) or ocular axial length (AL) in 0.01% atropine to the placebo groups, for accounting in the natural progression; and (2) the mean differences (MDs) in SER progression and AL elongation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A meta-analysis of 25 RCTs (4374 children aged 4\u201318) showed that 0.01% atropine reduced the SER progression by 37% annually (RoM: 0.63; 95% CI 0.54 to 0.74), with efficacy being much greater in South Asian populations (66% reduction; RoM: 0.34, 95% CI 0.27 to 0.42), than East Asian populations (35% reduction; RoM: 0.65, 95% CI 0.54 to 0.78) and white populations (28% reduction; RoM: 0.72, 95% CI 0.59 to 0.86) (p&lt;0.0001). Regarding the MD, 0.01% atropine was effective in slowing an overall myopia progression of 0.21D per year (95% CI 0.15D to 0.27D) compared with placebo group. A similar pattern was observed in AL elongation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>0.01% atropine effectively slows myopia progression across ethnicities, with the greatest efficacy observed in South Asian populations. Clinical practice should consider this ethnic difference to optimise the treatment effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>PROSPERO registration number<\/jats:title>\n                    <jats:p>CRD42025632545.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2025-328942","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:20:22Z","timestamp":1774372822000},"page":"1108-1117","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":2,"title":["Efficacy of 0.01% atropine eye drops for myopia control in children of different ethnicities: a systematic review and meta-analysis"],"prefix":"10.1136","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4197-1423","authenticated-orcid":false,"given":"Xiu Juan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"Queen Mary Hospital, Hong Kong, Hong Kong"},{"name":"The Hong Kong University-Shenzhen Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingming","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edison Chak Fung","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2825-8914","authenticated-orcid":false,"given":"Marco","family":"Yu","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute, Singapore National Eye Centre, Singapore"},{"name":"Eye-ACP, Duke-NUS Medical School, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan Tak Chun","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0021-3184","authenticated-orcid":false,"given":"Weijia","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezer","family":"Zaabaar","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip Yawen","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"The Hong Kong University-Shenzhen Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chen-wei","family":"Pan","sequence":"additional","affiliation":[{"name":"School of Public Health, Suzhou Medical College of Soochow University, Suzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yu","family":"Cheng","sequence":"additional","affiliation":[{"name":"Singapore Eye Research Institute, Singapore National Eye Centre, Singapore"},{"name":"Eye-ACP, Duke-NUS Medical School, Singapore"},{"name":"Department of Ophthalmology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"},{"name":"Centre for Innovation and Precision Eye Health, Yong Loo Lin School of Medicine, National University of Singapore, Singapore"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2156-1486","authenticated-orcid":false,"given":"Jason C","family":"Yam","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis Shun-chiu","family":"Lam","sequence":"additional","affiliation":[{"name":"The Primasia International Eye Research Institute (PIERI), School of Medicine, The Chinese University of Hong Kong (Shenzhen), Shenzhen, China"},{"name":"C-MER Dennis Lam Eye Center, C-MER International Eye Care Group Limited, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendrick","family":"Shih","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"Queen Mary Hospital, Hong Kong, Hong Kong"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher Kai Shun","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, The University of Hong Kong, Hong Kong, Hong Kong"},{"name":"Queen Mary Hospital, Hong Kong, Hong Kong"},{"name":"The Hong Kong University-Shenzhen Hospital, Shenzhen, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026092202200735000_110.10.1108.1","doi-asserted-by":"crossref","first-page":"100113","DOI":"10.1016\/j.apjo.2024.100113","article-title":"Is there an impending epidemic of myopia in Southeast Asia? An appraisal of the evidence","volume":"13","author":"Morgan","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026092202200735000_110.10.1108.2","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.4080","article-title":"Prevalence of myopia in children before, during, and after COVID-19 restrictions in Hong Kong","volume":"6","author":"Zhang","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026092202200735000_110.10.1108.3","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/j.survophthal.2023.07.006","article-title":"Pathogenesis of myopic choroidal neovascularization: a systematic review and meta-analysis","volume":"68","author":"Zhang","year":"2023","journal-title":"Surv Ophthalmol"},{"key":"2026092202200735000_110.10.1108.4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.24162"},{"key":"2026092202200735000_110.10.1108.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.09.020"},{"key":"2026092202200735000_110.10.1108.6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2011.07.031"},{"key":"2026092202200735000_110.10.1108.7","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","article-title":"Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology","volume":"124","author":"Pineles","year":"2017","journal-title":"Ophthalmology"},{"key":"2026092202200735000_110.10.1108.8","unstructured":"World Health Organization, Brien Holden Vision Institute . The impact of myopia and high myopia. Report of the Joint World Health Organization-Brien Holden Vision Institute Global Scientific Meeting on Myopia; 2015."},{"key":"2026092202200735000_110.10.1108.9","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-021-00822-y"},{"key":"2026092202200735000_110.10.1108.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.029"},{"key":"2026092202200735000_110.10.1108.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12886-023-03177-9","article-title":"Safety and efficacy of 0.01% and 0.1% low-dose atropine eye drop regimens for reduction of myopia progression in Danish children: a randomized clinical trial examining one-year effect and safety","volume":"23","author":"Hansen","year":"2023","journal-title":"BMC Ophthalmol"},{"key":"2026092202200735000_110.10.1108.12","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.14148"},{"key":"2026092202200735000_110.10.1108.13","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1001\/jamaophthalmol.2023.2855","article-title":"Low-dose 0.01% atropine eye drops vs placebo for myopia control: a randomized clinical trial","volume":"141","author":"Repka","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2026092202200735000_110.10.1108.14","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1164\/rccm.201607-1338OC","article-title":"Effort to breathe with various spontaneous breathing trial techniques: a physiologic meta-analysis","volume":"195","author":"Sklar","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"key":"2026092202200735000_110.10.1108.15","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.09.004"},{"key":"2026092202200735000_110.10.1108.16","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2019-315440"},{"key":"2026092202200735000_110.10.1108.17","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","article-title":"Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial","volume":"138","author":"Wei","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"2026092202200735000_110.10.1108.18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-01708-2","article-title":"Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial","volume":"11","author":"Cui","year":"2021","journal-title":"Sci Rep"},{"key":"2026092202200735000_110.10.1108.19","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-020-01658-0"},{"key":"2026092202200735000_110.10.1108.20","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-15686-6","article-title":"Efficacy of 0.01% atropine for myopia control in a randomized, placebo-controlled trial depends on baseline electroretinal response","volume":"12","author":"Chan","year":"2022","journal-title":"Sci Rep"},{"key":"2026092202200735000_110.10.1108.21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/APO.0000000000000609","article-title":"Atropine ophthalmic solution to reduce myopia progression in pediatric subjects: the randomized, double-blind multicenter phase II APPLE study","volume":"12","author":"Chia","year":"2023","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026092202200735000_110.10.1108.22","first-page":"477","article-title":"Efficacy of 0.01% atropine inmyopie children of different ages","volume":"23","author":"Hu","year":"2023","journal-title":"Guoji Yanke Zazhi (Int Eye Sci)"},{"key":"2026092202200735000_110.10.1108.23","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1159\/000528878","article-title":"Effect of atropine 0.01% eye drops on the difference in refraction and axial length between right and left eyes","volume":"66","author":"Liang","year":"2023","journal-title":"Ophthalmic Res"},{"key":"2026092202200735000_110.10.1108.24","doi-asserted-by":"crossref","first-page":"656","DOI":"10.47391\/JPMA.6241","article-title":"Effect of 0.01% atropine on diopter and optic axis in adolescents and children with myopia","volume":"73","author":"Xia","year":"2023","journal-title":"J Pak Med Assoc"},{"key":"2026092202200735000_110.10.1108.25","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2022-321272"},{"key":"2026092202200735000_110.10.1108.26","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1001\/jamaophthalmol.2024.2295","article-title":"0.01% atropine eye drops in children with myopia and intermittent exotropia: the AMIXT randomized clinical trial","volume":"142","author":"Wang","year":"2024","journal-title":"JAMA Ophthalmol"},{"key":"2026092202200735000_110.10.1108.27","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.oftal.2017.12.015","article-title":"Superdiluted atropine at 0.01% reduces progression in children and adolescents: a 5-year study of safety and effectiveness","volume":"93","author":"Diaz-Llopis","year":"2018","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"2026092202200735000_110.10.1108.28","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.jfo.2021.07.005","article-title":"Myopia progression and axial elongation in Spanish children: efficacy of atropine 0.01% eye-drops","volume":"44","author":"Moriche-Carretero","year":"2021","journal-title":"J Fr Ophtalmol"},{"key":"2026092202200735000_110.10.1108.29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","article-title":"Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3 years: a randomized clinical trial","volume":"141","author":"Zadnik","year":"2023","journal-title":"JAMA Ophthalmol"},{"key":"2026092202200735000_110.10.1108.30","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15761"},{"key":"2026092202200735000_110.10.1108.31","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2022-322808"},{"key":"2026092202200735000_110.10.1108.32","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3329\/bsmmuj.v13i4.50499","article-title":"Topical atropine in retarding myopia progression and axial length growth in children with myopia","volume":"13","author":"Alam","year":"2020","journal-title":"Bangabandhu Sheikh Mujib Medical University Journal"},{"key":"2026092202200735000_110.10.1108.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2021.01.026"},{"key":"2026092202200735000_110.10.1108.34","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.4103\/ijo.IJO_256_22","article-title":"Effect of atropine 0.01% on progression of myopia","volume":"70","author":"Sen","year":"2022","journal-title":"Indian J Ophthalmol"},{"key":"2026092202200735000_110.10.1108.35","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1080\/02713683.2022.2162925","article-title":"Low-dose atropine in preventing the progression of childhood myopia: a randomised controlled trial","volume":"48","author":"Sharma","year":"2023","journal-title":"Curr Eye Res"},{"key":"2026092202200735000_110.10.1108.36","first-page":"180","article-title":"Comparison of the effect of atropine and cyclopentolate on myopia","volume":"21","author":"Yen","year":"1989","journal-title":"Ann Ophthalmol"},{"key":"2026092202200735000_110.10.1108.37","doi-asserted-by":"crossref","first-page":"100122","DOI":"10.1016\/j.apjo.2024.100122","article-title":"Low-concentration atropine for controlling myopia onset and progression in East Asia","volume":"13","author":"Zaabaar","year":"2024","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026092202200735000_110.10.1108.38","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-88719-1","article-title":"Risk factors for rapid axial length elongation with low concentration atropine for myopia control","volume":"11","author":"Fu","year":"2021","journal-title":"Sci Rep"},{"key":"2026092202200735000_110.10.1108.39","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2025-328518"},{"key":"2026092202200735000_110.10.1108.40","article-title":"Interventions for myopia control in children: a living systematic review and network meta-analysis","volume":"2","author":"Lawrenson","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"2026092202200735000_110.10.1108.41","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1497667","article-title":"A systematic review with meta-analysis on the efficacy of 0.01% atropine eyedrops in preventing myopia progression in worldwide children\u2019s populations","volume":"16","author":"Navarra","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026092202200735000_110.10.1108.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.12.036"},{"key":"2026092202200735000_110.10.1108.43","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-43569-x","article-title":"Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression","volume":"13","author":"P\u00e9rez-Flores","year":"2023","journal-title":"Sci Rep"},{"key":"2026092202200735000_110.10.1108.44","doi-asserted-by":"publisher","DOI":"10.1136\/bjo-2023-324450"},{"key":"2026092202200735000_110.10.1108.45","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41433-018-0139-7","article-title":"Update in myopia and treatment strategy of atropine use in myopia control","volume":"33","author":"Wu","year":"2019","journal-title":"Eye (Lond)"},{"key":"2026092202200735000_110.10.1108.46","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1089\/jop.2011.0027","article-title":"The long-term results of using low-concentration atropine eye drops for controlling myopia progression in schoolchildren","volume":"27","author":"Wu","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"2026092202200735000_110.10.1108.47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ophtha.2024.06.010","article-title":"Hyperopic reserve as an indicator of myopia prevention by atropine (Low-Concentration Atropine for Myopia Prevention Study)","volume":"131","author":"Zhang","year":"2024","journal-title":"Ophthalmology"},{"key":"2026092202200735000_110.10.1108.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.11.010"},{"key":"2026092202200735000_110.10.1108.49","doi-asserted-by":"crossref","first-page":"100161","DOI":"10.1016\/j.apjo.2025.100161","article-title":"The whole life cycle myopia management","volume":"14","author":"Chen","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"2026092202200735000_110.10.1108.50","doi-asserted-by":"crossref","first-page":"100138","DOI":"10.1016\/j.apjo.2025.100138","article-title":"Role of caffeine in slowing progression of myopia: 1-year results from a prospective, longitudinal clinical trial","volume":"14","author":"Tran","year":"2025","journal-title":"Asia Pac J Ophthalmol (Phila)"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2025-328942","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T09:21:43Z","timestamp":1790068903000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2025-328942"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,24]]},"references-count":50,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,9,22]]},"published-print":{"date-parts":[[2026,10]]}},"alternative-id":["10.1136\/bjo-2025-328942"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2025-328942","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,24]]}}}